Concepedia

Fumio Nakagawa

FN

Statistics

Publications

40

Citations

1.5K

H-Index

23

Active since

1984

Affiliations

Taiho Pharmaceutical (Japan)(Current)

Biomedical Research Laboratories (United States)

Institute for Fermentation

Okayama Saiseikai General Hospital

Fumio Nakagawa is an author at Taiho Pharmaceutical (Japan) specializing in medicine, oncology, and pharmacology.

Publications per year

1984–2020

40

Publications

40

Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models

Nozomu Tanaka, Kazuki Sakamoto, Hiroyuki Okabe et al. · Oncology Reports · 2014 · 142 citations · Full text

, , +13

Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts

Hiroshi Tsukihara, Fumio Nakagawa, Kazuki Sakamoto et al. · Oncology Reports · 2015 · 109 citations · Full text

, , +17

A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells

Tomohiro Emura, Yuko Murakami, Fumio Nakagawa et al. · International Journal of Molecular Medicine · 2004 · 105 citations

, , +15

An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA

Tomohiro Emura, Fumio Nakagawa, Akio Fujioka et al. · International Journal of Molecular Medicine · 2004 · 85 citations

, , +16

Thymidylate synthase (TS) and ribonucleotide reductase (RNR) may be involved in acquired resistance to 5-fluorouracil (5-FU) in human cancer xenografts in vivo

Masakazu Fukushima, A Fujioka, Junji Uchida et al. · European Journal of Cancer · 2001 · 79 citations

, , +16

1–5 of 40